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Inflammatory BowelDiseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires
lifelong treatments. Probiotic microorganisms appear as an alternative for these patients; however, probiotic characteristics are
strain dependent and each probiotic needs to be tested to understand the underlining mechanisms involved in their beneficial
properties. Genetic modification of lactic acid bacteria (LAB) was also described as a tool for new IBD treatments. The first part of
this review shows different genetically modified LAB (GM-LAB) described for IBD treatment since 2000.Then, the two principally
studied strategies are discussed (i) GM-LAB producing antioxidant enzymes and (ii) GM-LAB producing the anti-inflammatory
cytokine IL-10. Different delivery systems, including protein delivery and DNA delivery, will also be discussed. Studies show the
efficacy of GM-LAB (using different expression systems) for the prevention and treatment of IBD, highlighting the importance of
the bacterial strain selection (with anti-inflammatory innate properties) as a promising alternative. These microorganisms could
be used in the near future for the development of therapeutic products with anti-inflammatory properties that can improve the
quality of life of IBD patients.
1. Introduction
Inflammatory Bowel Diseases (IBD) describe a group of dis-
orders of the gastrointestinal tract characterized by recurrent
inflammation, with periods of relapse and remission, and
epithelial injury. Ulcerative colitis (UC) and Crohn’s disease
(CD) are the two most frequent forms of IBD, clinically char-
acterized by different intestinal location, nature, and the his-
tological features of the inflammatory lesions as well as their
association with specific deregulation of the host’s immune
response. The exact etiology of these pathologies is still un-
known; however, it was described that in IBD patients there
existed aberrant features of the interaction between intestinal
microorganisms and gut immune and epithelial cells, which
is manifested as chronic intestinal inflammation [1].
IBD require lifelong treatments, and although they are
not generally associated with increased mortality, they can
cause significant morbidity. Probiotic microorganisms have
appeared as an alternative for IBD patients and their effi-
ciency has been analyzed in experimental animal models and
also in clinical trials [2, 3].
This paper will describe some of the mechanisms by
which probiotic microorganisms can exert specific benefits
against IBD, followed by a revision about the potential use of
genetically modify lactic acid bacteria in the prevention and
treatment of these recurrent diseases.
1.1. Mechanisms Involved in the Anti-Inflammatory Effects of
Probiotic Lactic Acid Bacteria. Lactic acid bacteria are the
most commonmicroorganisms used as probiotics. Because of
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specific documented beneficial effects, certain strains of LAB
have been designated as probiotics, which have been defined
as “live microorganisms that, when administered in adequate
amounts, confer a health benefit on the host” [4]. Among
these health benefits is the alleviation of IBD symptoms
which was reported for some probiotic LAB strains [3].
In this sense, it has been shown that LAB and other
probiotic microorganisms can counteract inflammatory pro-
cesses in the gastrointestinal tract (GIT) through different
mechanisms.
One of these is the modulation of the intestinal micro-
biota related to probiotic administration. It has been shown
that Lactobacillus (L.) reuteri could be used to prevent colitis
in IL-10−/− mice by increasing the number of lactobacilli in
the GIT [5]. In a placebo-controlled trial, the oral admin-
istration of L. salivarius UCC118 reduced the prevalence
of colon cancer and inflammatory activity in the mucosa
of IL-10−/− mice by modifying the intestinal microbiota
in these animals: Clostridium (C.) perfringens, coliforms,
and enterococci counts also decreased significantly in the
group treated with the probiotic [6]. Another mechanism
by which probiotics can have a positive effect is inhibiting
microorganisms through the production of antimicrobial
substances such as bacteriocins. Many bacteriocins produced
by various species ofLactobacillushave been reported [7].The
inhibitory activity of these bacteriocins varies from species to
species. It was reported that Lacticin 3147, a broad spectrum
bacteriocin produced by a Lactococcus (Lc.) lactis, inhibited
a wide range of genetically distinct C. difficile strains isolated
from healthy subjects and also from patients with IBD [8].
Numerous studies have shown that certain strains of LAB
may modulate the host’s immune response by regulating the
production of cytokines which are involved in regulation,
activation, growth, and differentiation of immune cells. One
of the ways by which probiotics may exert immunomod-
ulatory activities is by stimulating the production of IL-10
(an anti-inflammatory cytokine). However, not all probiotic
strains act in the same way. The anti-inflammatory effects
such as the stimulation of IL-10 producing cells are strain-
dependent characteristics, and their effectiveness is also
dependent on the concentrations used and the method of
administration.Thus, the anti-inflammatory effect associated
with the administration of a potential probiotic yoghurt to
mice was studied in models of acute and chronic intesti-
nal inflammation induced by trinitrobenzene sulfonic acid
(TNBS). Animals receiving yoghurt continuously improved
immune response with increases in IL-10 and decreases in IL-
17 (a proinflammatory cytokine) in the GIT of mice [9, 10]. In
another study it was shown that the anti-inflammatory strain
L. salivarius Ls 33 required the presence ofNOD2 receptors to
exert its protective effect, which was also related to the local
production of IL-10 [11]. By studying the expression of dif-
ferent genes, it was observed that the probiotic strain L. plan-
tarumLp91 caused a significant decrease in the levels of TNF𝛼
(tumor necrosis factor 𝛼) and COX-2 (cyclooxygenase-2) in
a mouse model of colitis, and this effect was related to signif-
icant increases of IL-10 expression [12]. It was also recently
observed, through the use of both in vitro and ex vivo studies,
that milk fermented with L. paracasei L74 CBA inhibited
proinflammatory cytokines without affecting the levels of
anti-inflammatory cytokines and that this anti-inflammatory
activity depended on metabolic products released during the
fermentation process [13]. A new study has also shown that a
strain of Streptococcus (S.) salivarius inhibited the activation
of the NF-𝜅B in vitro by demonstrating anti-inflammatory
properties in vivo [14].
The improvement of the intestinal barrier function is
another mechanism by which probiotic bacteria can benefit
the host. The exact mechanism by which probiotics enhance
the barrier function and the intestinal mucus is unclear;
however, it may be related to alterations in mucus secretion
or changes in intercellular interactions of the mucosa and cell
stability by modulating the phosphorylation of cytoskeletal
proteins and tight junctions [15, 16]. Oral treatment with
VSL # 3 (a mixture of eight probiotic bacteria including
Lactobacilli, Bifidobacterium, and Streptococcus species) nor-
malized the colonic physiological function and integrity of
the mucosal barrier in IL-10−/− mice [15]. L. plantarum DSM
9843 and L. reuteri R2LC also improved barrier function in a
model of enterocolitis induced by methotrexate in rats [17].
Some probiotic bacteria can modify the expression of muc
genes and mucus secretion [18].
Probiotic can also act by reducing oxidative stress, which
is characterized by an uncontrolled increase in the concen-
tration of reactive oxidative species (ROS) in the GIT. Thus,
another suggested mechanism to prevent inflammation by
LAB administration is through the expression of enzymes
that are be able to decrease the concentrations of ROS
or affect their formation. The levels of these enzymes are
often depleted in patients with IBD [19]. Probiotic LAB
expressing high levels of antioxidant enzymes could increase
these activities in specific locations of GIT and could then
contribute to the prevention of oxidative damage, leading to
potential applications for the treatment of IBD or posttherapy
treatments for IBD or even cancer patients. In this sense,
L. rhamnosus CNCM I-3690, selected for its antioxidant
properties in vitro, showed anti-inflammatory activity in a
model of colitis in vivo [20].
It is important to consider that probiotic characteristics
are strain dependent and each probiotic should be tested to
know if it has specific beneficial effects, and to describe the
mechanism/s involved in their health-promoting properties.
In addition, not many mechanisms are usually associated
with one individual strain. So, genetic modification of LAB
has been also described as a tool to development new treat-
ments for IBD, using microorganisms with GRAS (General
Recognized as Safe) status.
2. Genetically Modification of Lactic Acid
Bacteria for Treatment of IBD
It is theoretically possible, using genetic engineering tech-
niques, to obtain LAB strains that possess a variety of
beneficial properties. L. lactis is a LAB used in various
processes in the food industry and is has been characterized
because it does not survive in the digestive tract of animals
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and humans and thus has the potential to be used without
the possibility of survival through the gastrointestinal tract
[21]. L. lactis is normally used as a LAB model because
(i) its genome has been completely sequenced, (ii) it is
easy to manipulate genetically, and (iii) many genetic tools
have already been developed for this species. Based on the
identification and isolation of plasmids from native strains
of L. lactis and other LAB, several cloning vectors have been
developed. Usingmolecular biology techniques, these vectors
have been engineered to become important tools for cloning
genes of interest, and their products can be controlled with
constitutive or inducible promoters.
The development of efficient systems to express genes and
suitable protein secretion systems for use in LAB can permit
these microorganisms to be used for the production and
secretion of a number of heterologous proteins [22]. So, as
was explained above, LAB are potential candidates for use as
vehicles for the production and delivery of heterologous pro-
teins of technological, medical, or prophylactic interest and
several delivery systems are now available for those GRAS
microorganisms [23]. The introduction of genes coding for
antioxidant enzymes or cytokine production in LAB selected
for their probiotic potential, such as the ability to modulate
the immune response, may generate very useful strains that
can be applied in the treatment of a variety of inflammatory
diseases. However, before proposing the genetic modification
of anti-inflammatory strains, innate mechanisms of potential
vehicle strains should be demonstrated in appropriately
designed clinical trials on a large scale. These tests are
essential in future studies using genetically modified (GM)
strains to demonstrate the differences between wild type and
modified microorganisms.
The production of antioxidant enzymes and the produc-
tion of the anti-inflammatory cytokine IL-10 are two of the
most studied anti-inflammatory strategies using GM-LAB
and both will be revised in the following sections along with
a few examples of other anti-inflammatory compounds that
have successfully been produced by GM-LAB.
2.1. Lactic Acid Bacteria That Are Genetically Modified to
Produce Antioxidant Enzymes. As mentioned previously, in
patients with IBD, oxidative stress occurs as the result of
an abnormal and recurrent inflammation associated with
increased concentrations of ROS. Because few microorgan-
isms produce antioxidant enzymes in the concentrations
required to exert biological effects, genetic engineering strate-
gies have been used to obtain more efficient antioxidant
producing LAB. Spyropoulos et al. have shown the potential
uses of such strains in the treatment of IBD using a variety of
animal models [24]. LAB have been used to locally deliver
antioxidant enzymes such as superoxide dismutase (SOD)
directly in the intestines. This was a major breakthrough
because oral administration of SOD is largely limited by its
short half-life (5–10min) in the hostile conditions of the GIT.
It has been shown that GM strains of L. plantarum and L.
lactis that are able to produce and release SOD exhibited anti-
inflammatory effects in a TNBS induced colitis model [25].
Another experimental study showed the anti-inflammatory
activity L. gasseri strain producing SOD with an associated
reduction of the severity of colitis in IL-10 deficientmice [26].
L. casei BL23 producing SOD was able to significantly reduce
the damage induced by TNBS in mice as shown by increased
survival, decreased weight loss, lowermicrobial translocation
to liver, andmore importantly a decrease in the damage of the
large intestines [27].These results agree with others presented
previously inwhich the same strainwas able to slightly reduce
the histological damage degree in a dextran sulphate sodium
(DSS) induced colitis model [28].
Because L. lactis lacks catalase (as is also the case for most
LAB), the heme catalase gene katE from B. subtiliswas added
to this industrially important organism resulting in a GM
strain able to produce catalase that provided active catalase
activities [29]. It was demonstrated that this strain of L. lactis
producing catalase was able to prevent the development of
colon tumors inmice using a chemical inducedmodel [30]. In
another study, L. casei BL23 was modified to produce heme-
independent catalase and this in turn decreased the intestinal
inflammatory damage in a TNBS inducedmouse model [27].
This result is similar to those obtained previously in which
both the native strain L. casei BL23 and the derived GM
strain producing catalase reduced inflammation degrees in
the colon and cecumofmice, using aDSS inducedmodel [31].
S. thermophilus CRL807 is a strain that was present in
the starter mix, together with 12 other LAB, used to pre-
pare yoghurt with anti-inflammatory and anticancer effects
[9, 32]. The anti-inflammatory potential of this strain was
demonstrated in vitro and in vivo [33]. So, the concept that
LAB selected for their innate inflammatory potential can be
genetically modified to produced antioxidant enzymes and
obtain strains with more efficient anti-inflammatory effects
was recently evaluated using S. thermophilus CRL 807 [33].
Unlike other studies using GM L. lactis, it was observed that
the unmodified strain exerted anti-inflammatory effects in a
TNBS-induced colitis model in mice. It was also observed
that both genetically modified S. thermophilus CRL 807:CAT
and S. thermophilus CRL807:SOD (used as suspension or
in fermented milks) decreased the severity of inflammation,
and these beneficial changes were increased compared to
those observed in mice that received the wild type strain.
The mixture of both GM-streptococci were also evaluated
and shown to exert more anti-inflammatory properties than
when each strain was given individually. These results prove
that the use of LAB strains that are able to modulate the
immune response (innate capacity of S. thermophilus CRL
807) and also express antioxidant enzymes show a combined
effect andmay be a useful strategy in the development of new
therapeutics for patients suffering from IBD.
2.2. Genetically Modified LAB That Produce the Anti-Inflam-
matory Cytokine IL-10. Interleukin-10 (IL-10), as explained
in the introduction, is one of the major anti-inflammatory
cytokines involved in maintaining the homeostasis of the
intestinal immune response. It is recognized for its ability
to regulate inflammatory responses through the suppression
of the proinflammatory cytokine cascades [34], and this is
presented as a therapeutic candidate for the treatment of
IBD [35]. Furthermore, oral administration of the IL-10 is
not a viable option because of its extreme sensitivity to the
4 Gastroenterology Research and Practice
ambient of the GIT [36]. Although clinical trials conducted
to date have shown relatively poor results, the use of new
technologies for the delivery of IL-10 at the tissue level has
recently been suggested that could become a viable treatment
option for certain patients [37].Thus, different strategies were
designed to ensure that IL-10 reaches the GIT, including
the use of microencapsulation techniques or viral vectors
[38–40]. However, many of these methods are expensive,
complicated, or risky methodologically. Therefore, the use of
GM-LAB appeared as an attractive alternative for delivering
this cytokine at mucosal surface level [22].
The first evidence of GM-LAB as therapeutic vehicle for
IL-10 was published in 2000, when it was shown that a strain
of L. lactis secreting IL-10 prevented the onset of colitis in
IL-10−/− mice [41] and reduced inflammation in a model
of DSS induced colitis [42]. An important step for the safe
use of this GM-LAB for therapeutic purposes in humans
was the construction of a biological containment system in
a GM strain of L. lactis for intestinal delivery of human IL-10
cytokine [43]. In that study, the thymidylate synthase gene of
L. lactis was replaced by the human IL-10 gene, making this
strain unable to grow in the absence of thymidine or thymine.
This strain did not contain any antibiotic resistance marker
and since thymidine is auxotrophic, the strain could not be
spread to the environment making it one of the safest built
GM-LAB so far. This containment system was evaluated in
patients with CD and was shown not to produce any adverse
side effects, and these GM-LAB could only be recovered
in feces with the addition of thymidine [44]. However, the
clinical outcomes in these patients revealed no statistically
significances between those individuals who received the
GM-LAB compared with the placebo group. These results
showed the need to evaluate new methods of administration
to achieve a more effective delivery of IL-10 in the intestinal
mucosa using therapeutic LAB [45–49].
L. lactis subsp. lactis NCDO2118 pXYL:IL-10 is a LAB
that produced IL-10 using an expression system that has
a food-grade inducer in the xylose-inducible expression
system (XIES) [48]. Anti-inflammatory properties were also
described for the wild type strain (L. lactis subsp. lactis
NCDO2118) in a DSS induced colitis model in mice [50]. It
was demonstrated thatmilk fermented by L. lactisNCDO2118
pXYLCYT:IL-10, strain capable to produce and maintain IL-
10 in the bacterial cytoplasm, exerted an anti-inflammatory
effect in an acute TNBS inducedmodel of IBD inmice, which
was more pronounced than the ones observed with milk
fermented by the wild type strain [51]. This effect was related
to decreased levels of proinflammatory cytokines in the GIT
of mice. The results showed the use of fermented milks as a
new form of administration of IL-10 producing L. lactis. In
this system milk acts as a matrix to protect the bacteria and
the cytokine during the passage through the GIT. This new
approach could lead to the development of new therapeutic
fermented products (functional foods), appropriate for a
specific population that suffers gastrointestinal disorders.
L. lactis subsp. cremorisMG1363 pGroESL:IL-10 produces
IL-10 using the protein delivery expression system SICE
(Stress-Inducible Controlled Expression) and is based on a
stress inducible promoter (pGroESL) that allows the produc-
tion of the heterologous protein in situ (e.g., colon) [45]. L.
lactis capable of delivering the IL-10 protein using the SICE
system has the advantage that it does not require an inductor
because the adverse conditions of the GIT can by themselves
induce this system and all the IL-10 can be locally produced
by this LAB in the intestine. Recent studies showed that this
strain exerted a protective effect against inflammation in a
model of low-grade colon inflammation [52].
Even though protein delivery by GM-LAB showed
promising results, DNA delivery by GM-LAB was also evalu-
ated for the production of IL-10 locally by the host’s intestinal
cells. L. lactis subsp. cremorisMG1363 pValac:IL-10 is a GM-
LABused for the delivery of IL-10 cDNA.This system is based
on a new vector for DNA delivery using lactococci called
pValac (vaccination using lactic acid bacteria) that delivers
the DNA to the intestinal cells and gives these cells the
capacity to produce IL-10 directly at the site of inflammation
[46]. It was reported that L. lactis MG1363 engineered to
express fibronectin binding protein A (FnBPA) was used as
a vehicle to deliver the cDNA for IL-10 using the plasmid
pValac::il-10. L. lactisMG1363 FnBPA + pValac:IL-10 exerted
a significant anti-inflammatory effect in a TNBS induced
acute model of colitis in mice maintaining high ratios of
anti-/proinflammatory cytokines in the intestinal fluids and
tissues [53]. The importance of the presence of FnBPA in
the GM-LAB was demonstrated using a recombinant strain
of L. lactis that expresses FnBPA under the control of the
nisin inducible expression system [54]; however, the use
of the noninvasive strain L. lactis subsp. cremoris MG1363
pValac:IL-10 was also able to provide the IL-10 cDNA to the
host’s cells and exerted an in-inflammatory effect in a DSS
induced colitis model in mice [55] showing that this DNA
delivery system could be used in noninvasive strains.
The effectiveness of both protein and DNA delivery
systems was also recently compared using a TNBS induced
chronic inflammation model. It was demonstrated that L.
lactis pValac:IL-10 (noninvasive strain) exerted similar anti-
inflammatory effects than L. lactis pGroESL:IL-10, when
they were administered to the mice during the remission
period [56]. Even though the animals that received the strain
delivering IL-10 cDNA had higher levels of IL-10 in the
intestinal tissues, both systems were effective in maintaining
the remission of inflammation which is one of the major
problems in current IBD treatments.
2.3. Genetically Modified LAB That Produce Other Anti-
Inflammatory Compounds. Since TNF is one of the most
important proinflammatory cytokines in immune regulated
inflammatory processes, the objective of certain groups has
been not only to reduce the expression of this cytokine
but also to prevent it from being active. L. lactis was engi-
neered to secrete monovalent and bivalent murine (m)TNF-
neutralizing nanobodies as therapeutic proteins. It was shown
that the oral administration of nanobody-secreting L. lactis
resulted in local delivery of anti-mTNF nanobodies at the
colon that significantly reduced inflammation in DSS-induce
chronic colitis in mice [57].
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Interleukin-27 (IL-27) plays a role in the regulation of T
helper (Th) cell differentiation inducing Th1 differentiation
and suppressing immune responses. For this reason, it has
been proposed that IL-27 could be useful in therapy of dis-
eases mediated by inflammatory cytokines [58]. The 2 genes
encoding mouse IL-27 were introduced in L. lactis together
with a signal sequence which allowed for this cytokine to be
secreted.This IL-27 secreting strain was able to reduce colitis,
induced via transfer of CD4(+)CD45RB(hi) T cells into
Rag(−/−) mice, by increasing the production of IL-10 [59].
Transforming Growth Factor-𝛽1 (TGF-𝛽) is an inhibitory
cytokine recognized as a key regulator of immunological
homeostasis and inflammatory responses and was success-
fully expressed by L. lactis and when administered to DSS-
induced mice, this GM-LAB decreased colon damage scores
[60].
Besides immune regulators, other compounds have also
been shown to possess anti-inflammatory potential. The
Trefoil Factor (TFF) family of peptides, TFF1 (formerly pS2),
TFF2 (formerly spasmolytic peptide, SP), andTFF3 (formerly
Intestinal Trefoil Factor, ITF), is involved in the protection
of the gastrointestinal tract since they play an essential role
in epithelial restitution and repair of mucosal damage [61].
Intragastric administration of TFF-secreting L. lactis led to
active delivery of TFF at the mucosa of the colon and, in
contrast to administration of purified TFF, proved to be very
effective in prevention and healing of acute DSS-induced
colitis [62].These same authors then produced a mouth rinse
formulation ofL. lactis secreting humanTFF1which provided
a safe and efficient therapeutic tool for treating oral mucositis
[61].
It was previously shown that colonic tissues of patients
with IBD have increased proteolytic activity and that the
use of protease inhibitor Elafin was able to prevent intestinal
inflammation inmousemodels of colitis [63]. For this reason,
serine protease inhibitors such as Elafin and Secretory Leuko-
cyte Protease Inhibitor were expressed in recombinant L.
lactis and were shown to be very effective anti-inflammatory
molecules in a DSS-induced mouse model of colitis [60].
The enzyme 15-lipoxygenase-1 (15-LOX-1) is another
molecule that has been proposed as a potential candi-
date for the resolution of IBD because of its potent anti-
inflammatory action. It was shown that the administration
of milk fermented by a L. lactis strain 15-LOX-1 was effective
in the prevention of the intestinal damage associated with
inflammatory bowel disease in a TNBS murine model [64].
3. Risk Assessment of Genetically Modified
Lactic Acid Bacteria with
Anti-Inflammatory Properties
Although there is no scientific evidence to support the notion
that GMorganisms are dangerous for human consumption, it
is necessary to show that it is safe to use genetically modified
probiotics designed to extend the range of applications
covered by natural probiotics.
Consumption of GM microorganisms by human is still
a highly controversial issue due to the public perception that
geneticmanipulation is not “natural.” Scientists need through
well-designed studies to report the results for the general
population to inform consumers of the benefits that these
techniques can confer withminimal risk to the health and the
environment, such was the case of the IL-10 producing LAB
that was shown to be safe in human clinical trials [44].
4. Conclusions
The revision presented here not only showed the potential
associated with probiotic microorganisms to be used in
patients suffering diseases associated with gastrointestinal
inflammation, but also showed the potential use of GM-
LAB as new therapies for these patients. It is important
to restate the genetic modification of lactic acid bacteria
with innate anti-inflammatory properties to produce anti-
inflammatory compounds (such as antioxidant enzymes or
anti-inflammatory cytokines). It is a promissory tool to
obtain new more effective strains with potential applications
for IBD patients. These powerful strains should be given as
an adjunct treatment to current protocols for IBD patients,
and because of the beneficial properties, these could actually
improve the quality of life of these patients and aid in pre-
venting the unbalance of beneficial/pathogenic microbiota
present in the GIT.
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